Skip to main content

Table 2 Subgroup analyses for the outcome of relapse

From: Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

Subgroups No. of studies HR (95% CI) I2 (P value)
Population
 Children 5 3.30 (1.48–7.36) 73.1% (0.01)
 Adult 4 2.90 (1.85–4.57) 8.5% (0.35)
Design
 Prospective 7 4.21 (1.93–9.16) 62.2% (0.01)
 Retrospective 5 2.73 (1.96–3.79) 7.1% (0.37)
Region
 Europe 7 3.21 (1.80–5.71) 61.3% (0.02)
 USA 4 3.27 (2.00–5.36) 24.6% (0.26)
 Asia 1 7.34 (0.54–99.59)
Detection method
 PCR 7 3.82 (1.94–7.53) 62.0% (0.02)
 FC 4 3.10 (1.92–5.02) 17.0% (0.31)
Adjustment
 Adjusted 7 3.24 (2.10–5.00) 32.8% (0.18)
 Crude 5 3.43 (1.59–7.38) 64.6% (0.02)
Competing risk framework
 Yes 10 2.96 (2.22–3.96) 52.9%(0.02)
 No 2 2.40(1.45–3.98) 0.0 (0.39)